{"id":"NCT01299389","sponsor":"Janssen Pharmaceutical K.K.","briefTitle":"An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10","primaryCompletion":"2012-05","completion":"2012-05","firstPosted":"2011-02-18","resultsPosted":"2013-06-17","lastUpdate":"2013-06-17"},"enrollment":323,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Paliperidone palmitate","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Paliperidone palmitate","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of paliperidone palmitate as compared with placebo in the treatment of participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions \\[a false belief held in the face of strong differing evidence, especially as a symptom of psychiatric disorder\\] and hallucinations \\[imagining things\\], and withdrawal into the self).","primaryOutcome":{"measure":"Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation","timeFrame":"Baseline and Week 13 or early discontinuation","effectByArm":[{"arm":"Placebo (Double-blind)","deltaMin":83.5,"sd":15.18},{"arm":"Paliperidone Palmitate (Double-blind)","deltaMin":85.7,"sd":14.57}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":56,"countries":["Japan","South Korea","Taiwan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":25,"n":164},"commonTop":["Insomnia","Nasopharyngitis","Psychiatric symptom","Constipation","Injection site pain"]}}